This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dacheux, L.
Right arrow Articles by Barin, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dacheux, L.
Right arrow Articles by Barin, F.

 Previous Article  |  Next Article 

Journal of Virology, November 2004, p. 12625-12637, Vol. 78, No. 22
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.22.12625-12637.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Evolutionary Dynamics of the Glycan Shield of the Human Immunodeficiency Virus Envelope during Natural Infection and Implications for Exposure of the 2G12 Epitope

Laurent Dacheux,1 Alain Moreau,1 Yasemin Ataman-Önal,2 François Biron,3 Bernard Verrier,2 and Francis Barin1*

Laboratoire de Virologie, Equipe Associée 3856, Université François Rabelais, Tours,1 FRE 2736 CNRS-BioMérieux, Institut Fédératif de Recherche 128,2 Service des Maladies Infectieuses, Hôpital de la Croix-Rousse,Lyon, France3

Received 31 March 2004/ Accepted 13 July 2004

Elucidation of the kinetics of exposure of neutralizing epitopes on the envelope of human immunodeficiency virus type 1 (HIV-1) during the course of infection may provide key information about how HIV escapes the immune system or why its envelope is such a poor immunogen to induce broadly efficient neutralizing antibodies. We analyzed the kinetics of exposure of the epitopes corresponding to the broadly neutralizing human monoclonal antibodies immunoglobulin G1b12 (IgG1b12), 2G12, and 2F5 at the quasispecies level during infection. We studied the antigenicity and sequences of 94 full-length envelope clones present during primary infection and at least 4 years later in four HIV-1 clade B-infected patients. No or only minor exposure differences were observed for the 2F5 and IgG1b12 epitopes between the early and late clones. Conversely, the envelope glycoproteins of the HIV-1 quasispecies present during primary infection did not expose the 2G12 neutralizing epitope, unlike those present after several years in three of the four patients. Sequence analysis revealed major differences at potential N-linked glycosylation sites between early and late clones, particularly at positions known to be important for 2G12 binding. Our study, in natural mutants, confirms that the glycosylation sites N295, N332, and N392 are essential for 2G12 binding. This study demonstrates the relationship between the evolving "glycan shield " of HIV and the kinetics of exposure of the 2G12 epitope during the course of natural infection.


* Corresponding author. Mailing address: Laboratoire de Virologie, CHU Bretonneau, 37044 Tours cedex, France. Phone: 332 47 47 80 58. Fax: 332 47 47 36 10. E-mail: fbarin{at}med.univ-tours.fr.


Journal of Virology, November 2004, p. 12625-12637, Vol. 78, No. 22
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.22.12625-12637.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Beaumont, E., Vendrame, D., Verrier, B., Roch, E., Biron, F., Barin, F., Mammano, F., Brand, D. (2009). Matrix and Envelope Coevolution Revealed in a Patient Monitored since Primary Infection with Human Immunodeficiency Virus Type 1. J. Virol. 83: 9875-9889 [Abstract] [Full Text]  
  • Blay, W. M., Kasprzyk, T., Misher, L., Richardson, B. A., Haigwood, N. L. (2007). Mutations in Envelope gp120 Can Impact Proteolytic Processing of the gp160 Precursor and Thereby Affect Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Pseudoviruses. J. Virol. 81: 13037-13049 [Abstract] [Full Text]  
  • Quakkelaar, E. D., van Alphen, F. P. J., Boeser-Nunnink, B. D. M., van Nuenen, A. C., Pantophlet, R., Schuitemaker, H. (2007). Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies. J. Virol. 81: 8533-8542 [Abstract] [Full Text]  
  • Lambele, M., Labrosse, B., Roch, E., Moreau, A., Verrier, B., Barin, F., Roingeard, P., Mammano, F., Brand, D. (2007). Impact of Natural Polymorphism within the gp41 Cytoplasmic Tail of Human Immunodeficiency Virus Type 1 on the Intracellular Distribution of Envelope Glycoproteins and Viral Assembly. J. Virol. 81: 125-140 [Abstract] [Full Text]  
  • Pashov, A. D., Plaxco, J., Kaveri, S. V., Monzavi-Karbassi, B., Harn, D., Kieber-Emmons, T. (2006). Multiple Antigenic Mimotopes of HIV Carbohydrate Antigens: Relating Structure and Antigenicity. J. Biol. Chem. 281: 29675-29683 [Abstract] [Full Text]  
  • Blay, W.M., Gnanakaran, S., Foley, B., Doria-Rose, N. A., Korber, B. T., Haigwood, N. L. (2006). Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques. J. Virol. 80: 999-1014 [Abstract] [Full Text]  
  • Pashov, A., MacLeod, S., Saha, R., Perry, M., VanCott, T. C., Kieber-Emmons, T. (2005). Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12. Glycobiology 15: 994-1001 [Abstract] [Full Text]  
  • Qiao, Z.-S., Kim, M., Reinhold, B., Montefiori, D., Wang, J.-h., Reinherz, E. L. (2005). Design, Expression, and Immunogenicity of a Soluble HIV Trimeric Envelope Fragment Adopting a Prefusion gp41 Configuration. J. Biol. Chem. 280: 23138-23146 [Abstract] [Full Text]